Abstract
Antistaphylococcal penicillins such as nafcillin and oxacillin are among the first choices of treatment for severe invasive methicillin-susceptible Staphylococcus aureus (MSSA) infections, although there has been limited safety evaluations between individual agents. Using the FDA Adverse Event Reports System (FAERS), oxacillin was observed to have a lower proportion of reports of acute renal failure (reporting odds ratio [ROR], 5.3 [95% confidence interval {CI}, 3.1 to 9.3] versus 21.3 [95% CI, 15.8 to 28.6], respectively) and hypokalemia (ROR, 0.7 [95% CI, 0.1 to 4.8] versus 11.4 [95% CI, 7.1 to 18.3], respectively) than nafcillin.
Keywords:
drug safety; nafcillin; oxacillin; pharmacovigilance.
Copyright © 2020 American Society for Microbiology.
MeSH terms
-
Acute Kidney Injury / chemically induced*
-
Acute Kidney Injury / diagnosis
-
Acute Kidney Injury / pathology
-
Adverse Drug Reaction Reporting Systems / statistics & numerical data
-
Anti-Bacterial Agents / administration & dosage
-
Anti-Bacterial Agents / adverse effects*
-
Humans
-
Hypokalemia / chemically induced*
-
Hypokalemia / diagnosis
-
Hypokalemia / pathology
-
Nafcillin / administration & dosage
-
Nafcillin / adverse effects*
-
Odds Ratio
-
Oxacillin / administration & dosage
-
Oxacillin / adverse effects*
-
Patient Safety
-
Staphylococcal Infections / drug therapy*
-
Staphylococcal Infections / microbiology
-
Staphylococcal Infections / pathology
-
Staphylococcus aureus / drug effects
-
Staphylococcus aureus / growth & development
-
Staphylococcus aureus / pathogenicity
-
United States
-
United States Food and Drug Administration
Substances
-
Anti-Bacterial Agents
-
Nafcillin
-
Oxacillin